Researchers have harnessed artificial intelligence to uncover a new class of antimicrobial candidates, dubbed “prionin” peptides, hidden within prion and prion-like proteins. The study, detailed by GEN, identified molecules that reduced the burden of Acinetobacter baumannii — a notoriously drug-resistant pathogen — in a mouse model.
In the preclinical test, the most effective prionin peptides showed efficacy comparable to polymyxin B, a last-resort antibiotic. The findings suggest these naturally derived sequences could offer a fresh structural template for antibiotics, addressing a critical gap in the antimicrobial pipeline.
No clinical timeline has been disclosed. The research remains at an early bench stage, with no regulatory filings or human trials announced. The pathway from murine models to approved therapy typically spans years, even with accelerated pathways like the FDA’s Qualified Infectious Disease Product designation.
No company or stock data was reported. The work appears to have been conducted in academic or non-profit settings, with no immediate licensing or commercialization announcements. The global antimicrobial resistance crisis, which kills over a million people annually, underscores the potential value of such discoveries.
Experts caution that prion-derived therapeutics carry unique safety risks, given prions’ association with neurodegenerative diseases. The researchers have not released data on systemic toxicity or off-target effects, making clinical viability uncertain at this stage.